News Column

Hologic's Horizon DXA Platform for Osteoporosis, Cardiovascular Disease, and Obesity Assessment Receives Regulatory Approval in Canada

August 18, 2014

By a News Reporter-Staff News Editor at Cardiovascular Week -- Hologic, Inc. announced that Health Canada granted a medical device license for Horizon, a new DXA (dual-energy x-ray absorptiometry) imaging platform that assists in the assessment of three critical health problems - osteoporosis, cardiovascular disease, and obesity. Horizon was launched in the U.S. and other international markets in 2013 (see also Hologic, Inc.).

The Horizon DXA platform is designed to offer improved precision, stability and throughput over current products. New, clinically relevant built-in enhancements include a high-resolution multi-element detector array with ceramic detector technology for improved bone mapping and image quality; a high-frequency pulsing power supply that offers greater system stability and future flexibility; and a filter drum to support future development initiatives. Built on Hologic proprietary technologies, Horizon offers expanded technical capabilities, workflow efficiencies and improved design components to meet clinician needs now and into the future.

Keywords for this news article include: Obesity, Bariatrics, Cardiology, Hologic Inc., Overnutrition, Diet and Nutrition, Nutrition Disorders, Cardiovascular Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cardiovascular Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters